ADXS31-142 Alone and in Combination With Pembrolizumab (MK-3475) in Participants With Previously Treated Metastatic Castration-Resistant Prostate Cancer (mCRPC)

PHASE1/PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

June 4, 2015

Primary Completion Date

August 30, 2019

Study Completion Date

January 22, 2020

Conditions

CancerProstate Cancer

Interventions

DRUG

ADXS31-142

ADXS31-142 IV infusion

DRUG

Pembrolizumab

Pembrolizumab IV infusion

Trial Locations (8)

Recruiting, San Francisco

University of Colorado Health Sciences Center (UCHSC), Aurora

Recruiting, Rockville

Recruiting, Towson

New Brunswick

Recrutiing, Philadelphia

Site, Philadelphia

Recruiting, Providence